Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ConsumerLab ginkgo

This article was originally published in The Tan Sheet

Executive Summary

Nature's Way Ginkgold is one of only three ginkgo biloba supplements to pass online firm's test, ConsumerLab says April 21. Ten supplements were analyzed for levels of bilobalides, ginkgolides, overall terpene lactone levels and flavonol glycones based on "claimed amount of Ginkgo biloba leaf extract." ConsumerLab found seven of the products "lack[ed] adequate levels of one or more important compounds expected of clinically effective ginkgo." Similar testing conducted in 1999 found 75% of products tested met standards, compared with 22% in current review. Three out of four huperzine A products (often used for dementia, Alzheimer's disease) passed testing; the failed supplement was high in lead...

You may also be interested in...



Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095417

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel